Forusers of the popular depression drug Cymbalta there is new information abouthazardous side effects.  From a company release:
"Eli Lilly and Company would like to inform you of new saftey informationregarding hepatotoxicity with Cymbalta (duloxetine hydrochloride).  Thisinformation comes from postmarketing reports of hepatic injury (includinghepatitis and cholestatic jaundice).  Some of these reports indicate thatpatients with preexisting liver disease who take duloxetine may have anincreased risk for further liver damage.  The new labeling extends thePrecaution against using Cymbalta in patients with substantial alcohol use to includethose patients with chronic liver disease."
If you are taking Cymbalta it is important that you review this new informationand make any necessary changes.